Nasal semaglutide: does it exist, and what are your actual options in the UK?

You read about a nasal spray online (here's what that story actually refers to

Occasionally a research group publishes early work on transmucosal peptide delivery) that is, getting protein-based drugs like GLP-1 receptor agonists across a mucosal surface such as the nasal lining rather than injecting them under the skin. The concept is real science. The challenge is that semaglutide is a large peptide molecule, and the nasal mucosa is not reliably permeable to molecules of that size without specialist absorption enhancers. The handful of pre-clinical and very early-phase studies that have explored this have not progressed to late-stage trials.

When headlines use phrases like "semaglutide nasal" they are almost always describing conference speculation, animal studies, or patent applications rather than a product approaching clinical use. No pharmaceutical company has announced a licensed nasal semaglutide formulation. The MHRA has not approved one, and the medicines currently available to patients in the UK reflect what has actually completed the full evidence and regulatory process. Understanding that gap matters, because products sold online claiming to be nasal semaglutide are not licensed medicines. If no licensed product exists, there is nothing legitimate to buy in that form.

You can read about the licensed forms of semaglutide on our semaglutide overview page, which sets out what is actually approved and how each form works.

What changed in June 2026 — and why it matters if needles were putting you off

The most significant development for people looking for a non-injectable route is the oral Wegovy tablet. On 11 June 2026 the MHRA approved semaglutide tablets as the first oral GLP-1 medicine licensed in the UK for weight management, a genuine shift, and one the UK reached before any other European country.

The tablet contains the same active ingredient as the injection but is co-formulated with an absorption enhancer that allows it to be taken by mouth. The dosing schedule starts at 1.5 mg once daily and increases through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each level before moving up, and you can find a full breakdown of what the semaglutide 1 mg starting phase involves on our dedicated page. Taken first thing in the morning on an empty stomach with a small amount of plain water, then nothing else for at least thirty minutes, no coffee, no food, no other medicines. One thing patients tell us they appreciate: there is no refrigeration required, so it travels easily and fits into a morning routine without needing a trip to the fridge door first.

Trial data from the OASIS 4 study, involving 307 adults with obesity or overweight and at least one weight-related condition, showed an average weight loss of around 13.6% over 64 weeks compared with roughly 2.4% on placebo. Among participants who adhered fully to the tablet schedule, average loss was closer to 17%. Clinical trials like this are what the MHRA uses to assess whether a medicine is safe and effective enough to license, and why no nasal or inhaled form has reached that bar yet.

For more on what the evidence shows across the semaglutide programme, the Wegovy treatment page covers both the injection and the tablet in detail.

What the UK licensing landscape actually covers for semaglutide in 2026

Two licensed forms of semaglutide exist for weight management in the UK. Wegovy as a weekly subcutaneous injection, approved by the MHRA and recommended by NICE for eligible adults (TA875), has been available privately and through specialist NHS services for a few years. The process for getting Wegovy through a regulated online pharmacy involves a formal clinical consultation, identity and weight verification, and a prescription from a GPhC-registered prescriber.

The oral tablet, approved June 2026, is available privately on prescription; a NICE appraisal would be needed before it could be commissioned on the NHS. Both forms are licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea, used alongside a reduced-calorie diet and increased physical activity. Neither is licensed for under-18s, and neither is recommended during pregnancy, while breastfeeding, or when trying to conceive. The prescriber assesses the full clinical picture before any prescription is issued.

Semaglutide also holds a separate MHRA approval, granted 3 July 2026, for a form of fatty liver disease called MASH, though that indication is distinct from weight management. You can read about that on our semaglutide and liver disease page.

If you want to understand eligibility for the oral tablet or the injection, our weight-loss treatment overview is a useful starting point before booking a consultation. The week-by-week semaglutide guide gives a grounded sense of what treatment looks like in practice once it begins.

How to approach this safely if you're thinking about semaglutide treatment

The right question is not whether a nasal version is available (it isn't) but whether one of the two licensed forms suits your situation, and whether you meet the clinical criteria for treatment. That is a question for a prescriber, not a search engine.

What does not change across delivery routes is the legal framework: semaglutide for weight management is a prescription-only medicine in the UK. The MHRA has issued clear public guidance on GLP-1 medicines for weight loss, including warnings about products sold online that are not licensed, counterfeit, or supplied without a clinical assessment, guidance that applies to any claimed nasal semaglutide product just as much as it does to fake injection pens. You can report any suspected counterfeit or unlicensed medicine via the MHRA Yellow Card scheme.

At nume, every consultation is read and assessed by a GPhC-registered Independent Prescriber on the same day you submit it, a real clinician, working through the clinical picture, not an automated tool. If you would like to find out whether you are eligible for licensed semaglutide treatment, the clinical team behind nume is there to help. Check your eligibility by starting a free consultation.